Clinical Trial Update: An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease [Phase 3]

View source ↗

Summary

Open-label extension study evaluating safety and clinical utility of IPX066 in Parkinson's disease; completed Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IPX066 (carbidopa-levodopa formulation)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-03-03